Concert receives FDA breakthrough status for CTP-543 in alopecia areata
Concert Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata.